The Co-CEOs of Amylyx discuss Wednesday's news that they have acquired a GLP-1 antagonist as a new pipeline asset
Josh Cohen and Justin Klee explain why they chose this program, and what the potential timeline looks like for a phase 3 trial. Plus, an update on Amylyx's existing pipeline, including recent data in Wolfram Syndrome.